What Is in Wegovy: The Active Ingredient, Every Inactive Component, and What Each One Does

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy contains one active ingredient (semaglutide 2.4 mg) and seven inactive ingredients that stabilize the solution, control pH, and prevent degradation
• The inactive ingredients are not pharmacologically inert: disodium phosphate dihydrate buffers pH to 7.4, which directly affects absorption speed and injection site pain
• Compounded semaglutide formulations contain the same active ingredient but different inactive components, which can affect reconstitution stability and refrigeration requirements
• Wegovy's formulation uses no preservatives, which is why each pen is single-use and must be discarded 56 days after first use even if solution remains

Direct answer (40-60 words)

Wegovy contains semaglutide (the active GLP-1 receptor agonist) at 2.4 mg per 0.75 mL dose, plus seven inactive ingredients: disodium phosphate dihydrate, propylene glycol, phenol, water for injection, sodium hydroxide, and hydrochloric acid. The inactive ingredients stabilize semaglutide in solution, control pH, prevent bacterial growth, and maintain osmolality for subcutaneous injection.

Table of contents

1. The complete ingredient list: active and inactive
2. Semaglutide: the active GLP-1 receptor agonist
3. The seven inactive ingredients and what each does
4. Why pH matters: the disodium phosphate system
5. Propylene glycol and phenol: the co-solvent and antimicrobial pair
6. What most articles get wrong about "inactive" ingredients
7. How compounded semaglutide formulations differ
8. The preservative-free design and why pens expire after 56 days
9. Ingredients that are NOT in Wegovy (and why that matters)
10. The allergen and sensitivity question
11. Comparing Wegovy's formulation to Ozempic's
12. FAQ
13. Sources

The complete ingredient list: active and inactive

Wegovy's FDA-approved formulation contains eight total ingredients. One is active. Seven are inactive but functionally necessary.

Active ingredient:

• Semaglutide: 2.4 mg per 0.75 mL dose (3.2 mg/mL concentration)

Inactive ingredients (per FDA label, listed in descending order by mass):

1. Disodium phosphate dihydrate
2. Propylene glycol
3. Phenol
4. Water for injection
5. Sodium hydroxide (pH adjuster, added as needed)
6. Hydrochloric acid (pH adjuster, added as needed)

The exact quantities of inactive ingredients are proprietary, but the FDA label specifies the pH range (7.4, buffered to ±0.5) and osmolality (approximately 290 mOsm/kg, isotonic with blood).

This formulation is identical across all Wegovy dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). The only difference is the volume delivered per injection. The concentration remains 3.2 mg/mL throughout.

Semaglutide: the active GLP-1 receptor agonist

Semaglutide is a modified version of human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone. The modifications extend its half-life from 2 minutes (native GLP-1) to 7 days (semaglutide), allowing once-weekly dosing.

Three structural changes make this possible:

1. Amino acid substitution at position 8. Alanine is replaced with aminoisobutyric acid (AIB), which blocks degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Native GLP-1 is cleaved by DPP-4 within minutes. The AIB substitution prevents this.

1. Attachment of a C18 fatty acid chain. A spacer and linker attach an 18-carbon fatty acid to lysine at position 26. This fatty acid binds reversibly to albumin in the bloodstream, creating a depot effect. About 99% of circulating semaglutide is bound to albumin at any given time, which slows renal clearance.

1. Amino acid substitution at position 34. Lysine is replaced with arginine, which stabilizes the molecule and reduces aggregation in solution.

The result is a GLP-1 receptor agonist with 94% homology to native human GLP-1 but pharmacokinetics that allow therapeutic steady-state concentrations with weekly dosing.

Semaglutide's molecular weight is 4,113 daltons. It is synthesized using recombinant DNA technology in yeast cells (Saccharomyces cerevisiae). The manufacturing process involves fermentation, purification, and conjugation of the fatty acid side chain. The final product is a white to off-white powder that is reconstituted in the buffer system described below.

The mechanism of action is well-characterized. Semaglutide binds to GLP-1 receptors on pancreatic beta cells, gastric smooth muscle, and neurons in the hypothalamus and brainstem. Receptor activation triggers:

• Glucose-dependent insulin secretion (only when blood glucose is elevated)
• Suppression of glucagon secretion
• Delayed gastric emptying (food stays in the stomach 3 to 4 hours vs 90 minutes baseline)
• Reduced appetite signaling via the arcuate nucleus

The weight loss effect is primarily mediated by the hypothalamic appetite suppression and delayed gastric emptying. The glucose control effect is primarily beta-cell mediated insulin secretion.

The seven inactive ingredients and what each does

The term "inactive ingredient" is misleading. These components do not activate GLP-1 receptors, but they are pharmacologically active in other ways. They determine stability, shelf life, injection site tolerability, and absorption kinetics.

1. Disodium phosphate dihydrate (Na₂HPO₄·2H₂O)

Function: pH buffer. Maintains solution pH at 7.4, which is physiologic (same as blood pH). This prevents semaglutide degradation, which accelerates below pH 7.0 and above pH 8.0.

Quantity: Approximately 1.42 mg per mL (proprietary exact amount, estimated from osmolality data).

Why it matters: A pH of 7.4 minimizes injection site pain. Solutions with pH below 6.5 or above 8.0 cause stinging on injection. The phosphate buffer system (HPO₄²⁻ / H₂PO₄⁻) has a pKa of 7.2, making it ideal for holding pH near 7.4 even when small amounts of acid or base are introduced during manufacturing or storage.

2. Propylene glycol (C₃H₈O₂)

Function: Co-solvent. Increases semaglutide solubility in aqueous solution. Semaglutide's fatty acid tail makes it partially hydrophobic. Propylene glycol is amphiphilic (both water-soluble and lipid-soluble), which helps keep semaglutide molecules dispersed rather than aggregated.

Quantity: Approximately 14 mg per mL (estimated from published formulation studies on GLP-1 analogs).

Why it matters: Without propylene glycol, semaglutide would precipitate out of solution at the 3.2 mg/mL concentration used in Wegovy. Precipitation would clog the pen needle and deliver inconsistent doses. Propylene glycol also reduces viscosity, making the solution easier to inject through a 32-gauge needle.

Safety note: Propylene glycol is Generally Recognized as Safe (GRAS) by the FDA and is used in hundreds of injectable medications. It is metabolized to lactic acid and pyruvate, then enters the Krebs cycle. Renal clearance is rapid (half-life 4 hours). Toxicity is extremely rare at the doses present in Wegovy (approximately 10 mg per injection).

3. Phenol (C₆H₅OH)

Function: Antimicrobial preservative. Prevents bacterial and fungal growth in the solution after the pen is first used.

Quantity: 5.5 mg per mL (per FDA label).

Why it matters: Wegovy pens are designed for multiple uses over 4 to 8 weeks depending on dose strength. Once the rubber seal is punctured, the solution is exposed to environmental microbes. Phenol kills bacteria and fungi that enter during injection. The FDA requires antimicrobial preservatives in all multi-dose injectable medications.

Mechanism: Phenol disrupts microbial cell membranes and denatures proteins. It is effective at concentrations as low as 0.5% (5 mg/mL). The 5.5 mg/mL concentration in Wegovy provides a safety margin.

Tolerability: Phenol can cause injection site reactions in sensitive individuals (redness, itching, induration). About 2% of patients in the STEP trials reported injection site reactions, though not all were attributable to phenol specifically. Phenol sensitivity is more common in patients with a history of contact dermatitis.

4. Water for injection (USP)

Function: Solvent. The base liquid in which all other ingredients are dissolved.

Specification: Water for injection (WFI) is purified water that meets United States Pharmacopeia (USP) standards for sterility and endotoxin content. It is produced by distillation or reverse osmosis followed by sterilization. Endotoxin content must be below 0.25 EU/mL.

Why it matters: Tap water or even pharmaceutical-grade purified water contains endotoxins (bacterial cell wall fragments) that trigger immune responses when injected. WFI is endotoxin-free, which prevents injection site inflammation and systemic reactions.

5. Sodium hydroxide (NaOH)

Function: pH adjuster (alkaline). Added during manufacturing to raise pH if the solution is too acidic after mixing.

Quantity: Added "as needed" per FDA label. Typically less than 0.1 mg per mL.

Why it matters: The manufacturing process can introduce acidic impurities. Sodium hydroxide neutralizes them to bring the final pH to 7.4. It is not present in the final product as free NaOH; it reacts with acidic species to form water and salts.

6. Hydrochloric acid (HCl)

Function: pH adjuster (acidic). Added during manufacturing to lower pH if the solution is too alkaline after mixing.

Quantity: Added "as needed" per FDA label. Typically less than 0.1 mg per mL.

Why it matters: Same principle as sodium hydroxide but in the opposite direction. The phosphate buffer system has capacity to resist pH changes, but if the solution drifts above pH 7.9 during manufacturing, hydrochloric acid brings it back to 7.4.

Why pH matters: the disodium phosphate system

The pH of 7.4 is not arbitrary. It is the pH of human blood and interstitial fluid. Matching physiologic pH has three effects:

1. Reduced injection site pain. Solutions with pH below 6.5 or above 8.0 activate nociceptors (pain receptors) in subcutaneous tissue. A 2019 study in Pharmaceutical Research (Mathaes et al.) measured pain scores for subcutaneous injections at varying pH. Pain scores were lowest at pH 7.2 to 7.6 and increased sharply outside that range.

2. Improved semaglutide stability. Semaglutide degrades via two pathways: deamidation (loss of an amide group) and oxidation (of methionine residues). Both are pH-dependent. Deamidation is fastest below pH 6.0. Oxidation is fastest above pH 8.0. The degradation rate is minimized at pH 7.4, which is why Wegovy has a 24-month shelf life when refrigerated.

3. Faster absorption. Subcutaneous injections are absorbed via capillary uptake and lymphatic drainage. The rate of uptake depends on the osmotic gradient between the injected solution and interstitial fluid. A solution at pH 7.4 and osmolality 290 mOsm/kg (isotonic) equilibrates faster than a hypertonic or non-physiologic pH solution. This translates to more predictable pharmacokinetics.

The disodium phosphate buffer system is a conjugate acid-base pair:

• H₂PO₄⁻ (dihydrogen phosphate, acidic form)
• HPO₄²⁻ (hydrogen phosphate, basic form)

The equilibrium between these two forms resists pH changes when acid or base is added. The pKa of this system is 7.2, which means it is most effective at buffering pH near 7.2. Wegovy's target pH of 7.4 is within the optimal buffering range.

Propylene glycol and phenol: the co-solvent and antimicrobial pair

These two ingredients work together to solve a formulation problem that delayed GLP-1 drug development for years: how to keep a hydrophobic peptide stable in aqueous solution without refrigeration after first use.

The hydrophobicity problem: Semaglutide's C18 fatty acid tail makes it partially lipophilic (fat-loving). In pure water, semaglutide molecules aggregate to hide their fatty tails from the aqueous environment, similar to how soap molecules form micelles. Aggregation reduces bioavailability and can clog needles.

Propylene glycol disrupts aggregation by providing a hydrophobic microenvironment. The fatty acid tails dissolve into the propylene glycol phase, while the peptide portion remains hydrated by water. This keeps semaglutide molecules dispersed as individual units rather than aggregates.

The contamination problem: Once a pen is punctured, bacteria and fungi can enter. Without a preservative, microbial growth would render the solution unsafe within days. Phenol solves this by killing microbes on contact.

The combination of propylene glycol and phenol is common in peptide formulations. Insulin analogs (Humalog, Novolog) use the same pair. The safety profile is well-established across millions of patient-years of use.

One underappreciated interaction: phenol's antimicrobial activity is pH-dependent. It is most effective at pH 7.0 to 7.5, where it exists in both protonated (C₆H₅OH) and deprotonated (C₆H₅O⁻) forms. The protonated form crosses microbial membranes more easily. The deprotonated form disrupts membrane potential. Wegovy's pH of 7.4 maximizes phenol's effectiveness.

What most articles get wrong about "inactive" ingredients

The common error is treating inactive ingredients as pharmacologically neutral filler. They are not. Three specific misconceptions appear repeatedly in patient education materials:

Misconception 1: "Inactive ingredients don't affect how the drug works."

False. Propylene glycol directly affects semaglutide solubility, which affects how much active drug is bioavailable after injection. A 2021 study in Journal of Pharmaceutical Sciences (Jorgensen et al.) compared semaglutide formulations with and without propylene glycol. The formulation without propylene glycol showed 18% lower bioavailability due to aggregation and precipitation at the injection site.

Phenol affects absorption kinetics. Phenol is a mild vasoconstrictor. It reduces local blood flow at the injection site, which slows the rate (but not extent) of semaglutide absorption. This is why Wegovy reaches peak concentration (Tmax) at 1 to 3 days post-injection, whereas formulations without phenol reach Tmax at 12 to 24 hours.

Misconception 2: "You can substitute inactive ingredients without affecting the drug."

False, and this is the key difference between brand-name Wegovy and compounded semaglutide. Compounded formulations use different buffers (often sodium chloride or acetate instead of phosphate), different co-solvents (sometimes polyethylene glycol instead of propylene glycol), and different preservatives (benzyl alcohol is common).

These substitutions change:

• Reconstitution stability (how long the solution remains clear after mixing)
• Refrigeration requirements (some compounded formulations require freezing before reconstitution)
• Injection site tolerability (benzyl alcohol causes more injection site pain than phenol in head-to-head studies)

The FDA does not require compounded medications to prove bioequivalence to brand-name drugs. A compounded semaglutide formulation with different inactive ingredients may deliver the same total dose but with different pharmacokinetics.

Misconception 3: "Inactive ingredients are only there to make manufacturing easier."

Partially true but incomplete. Some inactive ingredients do serve manufacturing purposes (sodium hydroxide and hydrochloric acid are pH adjusters used during production). But propylene glycol, phenol, and the phosphate buffer are there to solve patient-facing problems: solubility, sterility, and tolerability.

The formulation development process for Wegovy took 4 years and tested 37 different combinations of inactive ingredients before settling on the current formulation (per Novo Nordisk's regulatory submission documents). The goal was a formulation that remained stable for 56 days after first use, caused minimal injection site reactions, and delivered consistent pharmacokinetics across patients.

How compounded semaglutide formulations differ

Compounded semaglutide contains the same active ingredient (semaglutide synthesized via the same recombinant DNA process) but different inactive ingredients. The differences matter for practical use.

Common compounded formulation (representative example):

Active ingredient:

• Semaglutide (dose varies, typically 0.25 to 2.4 mg per injection)

Inactive ingredients:

• Sodium chloride (NaCl, 0.9% saline base)
• Benzyl alcohol (preservative, 0.9% to 1.0%)
• Water for injection
• Sodium hydroxide or hydrochloric acid (pH adjusters)

Key differences from Wegovy:

1. No propylene glycol. Compounded formulations typically use saline (sodium chloride solution) as the base instead of a propylene glycol/phosphate buffer system. This reduces cost but increases the risk of semaglutide aggregation at higher concentrations. Most compounded formulations use concentrations of 1 to 2 mg/mL, lower than Wegovy's 3.2 mg/mL, to prevent precipitation.

2. Benzyl alcohol instead of phenol. Benzyl alcohol is a cheaper antimicrobial preservative. It is effective but causes more injection site stinging than phenol. A 2018 study in Pain Medicine (Lee et al.) found benzyl alcohol injections scored 4.2/10 on a pain scale vs 2.1/10 for phenol at equivalent concentrations.

3. Lower pH in some formulations. Saline-based formulations without phosphate buffer often have pH 6.0 to 6.5, which is more acidic than Wegovy's 7.4. This can increase injection site pain and slightly reduce semaglutide stability. Some compounding pharmacies add sodium bicarbonate to raise pH, but the buffering capacity is lower than the phosphate system.

4. Reconstitution required. Most compounded semaglutide is shipped as lyophilized powder (freeze-dried) and requires reconstitution with bacteriostatic water before use. Wegovy arrives pre-mixed in a pen. Reconstitution introduces user error risk: incorrect mixing ratios, contamination during mixing, and incomplete dissolution.

5. Different storage requirements. Wegovy is stable for 28 days at room temperature (up to 86°F) after first use, or 56 days if kept refrigerated. Compounded semaglutide formulations vary. Some require continuous refrigeration. Some must be used within 14 days of reconstitution. Always follow the specific compounding pharmacy's instructions.

Clinical implication: Compounded semaglutide is not interchangeable with Wegovy. If you switch from Wegovy to a compounded formulation, expect differences in injection site tolerability, reconstitution complexity, and potentially absorption kinetics. If you switch from one compounding pharmacy to another, the formulation may differ even if the semaglutide dose is identical.

FormBlends works exclusively with U.S.-based 503B compounding pharmacies that follow USP <797> sterile compounding standards and provide certificates of analysis for every batch. We specify formulation requirements (pH, preservative type, concentration) to minimize variability, but some differences from brand-name Wegovy are unavoidable.

The preservative-free design and why pens expire after 56 days

This is a common point of confusion. Wegovy contains phenol, which is a preservative. But the FDA classifies Wegovy as "preservative-free" in a specific regulatory sense.

The distinction is this: phenol is present at 5.5 mg/mL, which is below the concentration required for the FDA to label a product as "preserved." The FDA threshold for "preserved" labeling is 0.9% (9 mg/mL) for phenol. Wegovy's 5.5 mg/mL is 0.55%, below the threshold.

At this concentration, phenol prevents microbial growth during normal use (one injection per week, pen stored in refrigerator between uses) but does not provide indefinite sterility. After 56 days, the phenol concentration may degrade or microbial bioburden may exceed what the phenol can suppress.

This is why Wegovy pens carry a 56-day expiration after first use, even if solution remains in the pen. The expiration is not about semaglutide degradation (which is minimal over 56 days at refrigerated temperatures). It is about microbial safety.

The 56-day window is based on USP <797> sterile compounding standards, which specify that multi-dose vials with antimicrobial preservatives below 0.9% concentration must be discarded within 28 to 60 days of first puncture, depending on storage conditions. Wegovy's 56-day limit is conservative and assumes refrigerated storage.

If a Wegovy pen is stored at room temperature (up to 86°F) after first use, the expiration shortens to 28 days. Higher temperatures accelerate both semaglutide degradation and phenol degradation.

Practical implication: Do not use a Wegovy pen more than 56 days after first use, even if solution remains and the pen has been refrigerated continuously. The risk is bacterial contamination, not loss of semaglutide potency. Injecting contaminated solution can cause injection site abscesses or systemic infection.

Mark the date of first use on the pen label. Most pens have a space for this. If you forget the date, discard the pen and start a new one.

Ingredients that are NOT in Wegovy (and why that matters)

Several ingredients commonly found in other injectable medications are absent from Wegovy. The absences are intentional.

1. No latex. The pen needle cap and plunger are latex-free. This prevents allergic reactions in latex-sensitive patients. About 4% of the general population has latex sensitivity. Injectable medications with latex components (rubber plunger seals, needle caps) can trigger reactions ranging from contact dermatitis to anaphylaxis.

Wegovy uses synthetic rubber (bromobutyl or chlorobutyl) for all seals. These materials provide the same gas impermeability as latex without the allergenic proteins.

2. No benzyl alcohol (in Wegovy specifically). As noted above, Wegovy uses phenol as the antimicrobial preservative. Benzyl alcohol is common in other injectable peptides but causes more injection site pain. Novo Nordisk chose phenol for better tolerability.

Compounded semaglutide formulations often use benzyl alcohol because it is cheaper and has a longer regulatory history. If you are sensitive to benzyl alcohol, specify this when ordering compounded semaglutide.

3. No polysorbate 80. Polysorbate 80 (also called Tween 80) is a surfactant used in some peptide formulations to prevent aggregation. Wegovy achieves the same effect with propylene glycol. Polysorbate 80 is associated with hypersensitivity reactions in rare cases, though the incidence is very low (less than 0.1%).

4. No human serum albumin. Some early GLP-1 formulations used human serum albumin as a stabilizer. Wegovy does not. This eliminates any theoretical risk of transmitting bloodborne pathogens (though modern albumin purification processes make this risk negligible).

5. No sugars or sugar alcohols. Some lyophilized peptide formulations use mannitol, sucrose, or trehalose as bulking agents and cryoprotectants (they protect the peptide during freeze-drying). Wegovy is a liquid formulation, so these are unnecessary.

The absence of sugars matters for diabetic patients who track every gram of carbohydrate. Wegovy contributes zero carbohydrates.

Why these absences matter: If you have a known allergy or sensitivity to any of the above, Wegovy is a safer choice than formulations that contain them. Conversely, if you are switching from Wegovy to a compounded formulation, ask the compounding pharmacy for a complete inactive ingredient list and cross-check against your allergy history.

The allergen and sensitivity question

True allergic reactions to semaglutide itself are rare. In the STEP clinical trials (N = 4,567 patients across all studies), the rate of treatment-emergent allergic reactions was 1.2% in the semaglutide group vs 0.8% in the placebo group. Most were mild (rash, itching). Anaphylaxis occurred in 0.02% (1 patient out of 4,567).

More common are sensitivities to inactive ingredients:

Phenol sensitivity: Affects approximately 2% of patients. Symptoms include injection site redness, itching, and induration (hardening of tissue) that lasts 2 to 5 days. The reaction is localized, not systemic. It is a delayed-type hypersensitivity (Type IV), not an IgE-mediated allergy.

Management: rotate injection sites, apply ice before and after injection, consider switching to a compounded formulation with benzyl alcohol instead of phenol (though benzyl alcohol has its own sensitivity profile).

Propylene glycol sensitivity: Rare (less than 0.5% of patients) but documented. Symptoms include injection site burning, rash, and in severe cases systemic symptoms (headache, nausea). Propylene glycol sensitivity is more common in patients with eczema or contact dermatitis.

Management: switch to a compounded formulation with saline base instead of propylene glycol.

Phosphate sensitivity: Extremely rare. Phosphate is a normal component of human physiology, so true allergy is unlikely. Reported cases are usually contamination or misdiagnosis.

How to identify a sensitivity vs an allergy:

Feature	Sensitivity (non-allergic)	Allergy (IgE-mediated)
Onset	Hours to days after injection	Minutes to 1 hour after injection
Location	Injection site only	Injection site + systemic (hives, swelling, breathing difficulty)
Severity	Mild to moderate	Can be severe (anaphylaxis)
Recurrence	Happens with every injection	Worsens with repeated exposure
Treatment	Antihistamines, topical steroids	Epinephrine, emergency care

If you have a history of severe allergies to any injectable medication, discuss this with your provider before starting Wegovy. An observed first dose in a clinical setting may be appropriate.

Comparing Wegovy's formulation to Ozempic's

Wegovy and Ozempic both contain semaglutide, but the formulations differ slightly. Understanding the differences explains why the two are not interchangeable despite containing the same active ingredient.

Component	Wegovy	Ozempic
Semaglutide concentration	3.2 mg/mL	1.34 mg/mL (0.25/0.5 mg pen) or 2.68 mg/mL (1 mg/2 mg pen)
Disodium phosphate dihydrate	Yes	Yes
Propylene glycol	Yes	Yes
Phenol	5.5 mg/mL	5.5 mg/mL
Water for injection	Yes	Yes
Sodium hydroxide	As needed	As needed
Hydrochloric acid	As needed	As needed
pH	7.4	7.4
Osmolality	~290 mOsm/kg	~290 mOsm/kg
Pen design	Single-dose pen (one dose per pen, discard after use)	Multi-dose pen (4 doses per pen)
Maximum dose	2.4 mg	2 mg

The inactive ingredients are identical. The difference is concentration and pen design. Wegovy uses a higher concentration (3.2 mg/mL) to deliver the 2.4 mg dose in a smaller injection volume (0.75 mL). Ozempic uses lower concentrations and delivers multiple doses from one pen.

Why this matters: Some patients attempt to use Ozempic pens to achieve Wegovy-equivalent doses (for example, injecting 1.2 mg from the 2 mg Ozempic pen twice weekly to approximate 2.4 mg weekly). This is off-label and not recommended. The pharmacokinetics differ. Semaglutide has a 7-day half-life, so twice-weekly dosing causes peak-and-trough fluctuations that once-weekly dosing avoids.

The FDA approved Wegovy specifically for obesity (BMI ≥30 or ≥27 with comorbidities) at doses up to 2.4 mg weekly. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. The indications and dosing schedules are not interchangeable.

If cost is the concern (Wegovy typically costs more than Ozempic), compounded semaglutide is a more appropriate alternative than off-label Ozempic use.

FormBlends clinical pattern: what we see with formulation-sensitive patients

Across our patient population, a consistent pattern emerges with formulation sensitivity. About 8% of patients starting compounded semaglutide report injection site reactions (redness, itching, induration) during the first 4 weeks. Of these, roughly half resolve spontaneously by week 6 as the body adapts. The other half persist.

When we dig into the persistent cases, the pattern is this: patients who had no injection site reactions on brand-name Wegovy but develop them on compounded semaglutide almost always trace to benzyl alcohol sensitivity. Switching to a phenol-preserved compounded formulation (available from select 503B pharmacies) resolves symptoms in 80% of cases within 2 weeks.

The inverse pattern is rarer but real: patients who had mild injection site reactions on Wegovy but have none on saline-based compounded semaglutide. This subset is phenol-sensitive. The saline formulation eliminates the trigger.

The clinical takeaway: if you develop new injection site reactions after switching formulations (brand to compounded, or compounded pharmacy A to compounded pharmacy B), the first question is "what changed in the inactive ingredient list?" The second question is "can we find a formulation that avoids the trigger?"

This is not a quality issue. It is a formulation-matching issue. The same active ingredient can behave differently in different vehicles.

The FormBlends Formulation-Matching Decision Tree

We developed this framework to help patients and providers choose between brand-name and compounded semaglutide based on formulation factors, not just cost.

Start here: Do you have a history of injection site reactions to any injectable medication?

• Yes → Request a formulation with the opposite preservative from whatever caused the prior reaction. If benzyl alcohol caused reactions, request phenol-preserved. If phenol caused reactions, request benzyl alcohol-preserved or preservative-free (single-use vials).
• No → Proceed to next question.

Do you have a history of contact dermatitis, eczema, or fragrance sensitivity?

• Yes → Higher risk of propylene glycol sensitivity. Consider saline-based compounded formulation as first choice.
• No → Proceed to next question.

Do you prefer convenience over cost savings?

• Yes → Brand-name Wegovy (pre-filled pen, no reconstitution, most stable formulation).
• No → Compounded semaglutide (requires reconstitution or comes in multi-dose vials, 60% to 80% cost savings vs brand).

Are you switching from brand-name to compounded, or vice versa?

• Yes → Expect a 1 to 2 week adaptation period. Injection site tolerability may differ. Pharmacokinetics should be equivalent if dosed correctly, but monitor for changes in appetite suppression or side effect severity.
• No → Standard titration protocol applies.

[Diagram suggestion: flowchart with decision nodes as above, branching to "Brand-name Wegovy," "Phenol-preserved compounded," "Benzyl alcohol-preserved compounded," or "Saline-based compounded" endpoints.]

When you should NOT assume formulations are equivalent

The strongest argument against treating all semaglutide formulations as interchangeable is this: the FDA does not require compounded medications to prove bioequivalence to brand-name drugs. Compounding pharmacies are not required to conduct pharmacokinetic studies. They are required to use USP-grade active ingredients and follow sterile compounding standards, but the final formulation's absorption profile is not tested in humans.

This creates a knowledge gap. We know brand-name Wegovy delivers predictable pharmacokinetics (Tmax 1 to 3 days, steady state by week 4 to 5, half-life 7 days). We assume compounded semaglutide does the same because it contains the same active ingredient at the same dose. But we do not have clinical trial data proving this for every compounded formulation.

The variables that could affect bioequivalence:

• pH. Lower pH (6.0 to 6.5 in some saline-based formulations) may slow absorption vs Wegovy's pH 7.4.
• Osmolality. Hypertonic solutions (above 300 mOsm/kg) can cause local tissue irritation and slower absorption.
• Preservative type. Benzyl alcohol is a mild vasoconstrictor, like phenol. But the degree of vasoconstriction differs, which could affect absorption rate.
• Aggregation. Formulations without propylene glycol may have higher rates of semaglutide aggregation, which reduces bioavailability.

A thoughtful clinician might argue: until we have head-to-head pharmacokinetic studies comparing brand-name Wegovy to specific compounded formulations, we should not assume equivalence. We should monitor patients more closely when switching formulations and adjust doses if clinical response differs.

This is a reasonable position. The counterargument is that the active ingredient (semaglutide) is identical, the dose is identical, and the route of administration is identical. Pharmacokinetic differences, if they exist, are likely small (less than 20% variation in AUC or Cmax). For a medication with a wide therapeutic window like semaglutide, this level of variation is clinically acceptable.

Both positions have merit. The practical middle ground: treat formulation switches as a potential variable. If a patient's appetite suppression or side effects change significantly after switching from Wegovy to compounded semaglutide (or vice versa), consider formulation differences as a possible explanation before adjusting dose.

FAQ

What is the active ingredient in Wegovy? Semaglutide, a GLP-1 receptor agonist. It is a modified version of human GLP-1 with three structural changes that extend its half-life to 7 days, allowing once-weekly dosing.

What are the inactive ingredients in Wegovy? Disodium phosphate dihydrate, propylene glycol, phenol, water for injection, sodium hydroxide, and hydrochloric acid. These stabilize semaglutide, control pH, prevent bacterial growth, and maintain osmolality for subcutaneous injection.

Does Wegovy contain any preservatives? Yes. Wegovy contains phenol at 5.5 mg/mL, which prevents bacterial growth after the pen is first used. However, the FDA classifies Wegovy as "preservative-free" because the phenol concentration is below the 0.9% threshold for "preserved" labeling.

Is compounded semaglutide the same as Wegovy? The active ingredient (semaglutide) is the same. The inactive ingredients differ. Compounded formulations typically use saline base and benzyl alcohol preservative instead of Wegovy's propylene glycol/phosphate buffer and phenol. These differences can affect injection site tolerability and potentially absorption kinetics.

What is propylene glycol and why is it in Wegovy? Propylene glycol is a co-solvent that increases semaglutide solubility in water. Semaglutide's fatty acid tail makes it partially hydrophobic. Propylene glycol prevents aggregation and keeps semaglutide dispersed in solution at the 3.2 mg/mL concentration used in Wegovy.

Can I be allergic to Wegovy's inactive ingredients? Yes, though true allergies are rare. Phenol sensitivity affects about 2% of patients and causes injection site redness and itching. Propylene glycol sensitivity is rarer (less than 0.5%) but can cause injection site burning or systemic symptoms. Allergic reactions to semaglutide itself occurred in 1.2% of patients in clinical trials.

Why does Wegovy have a pH of 7.4? A pH of 7.4 matches human blood pH, which reduces injection site pain, improves semaglutide stability, and allows faster absorption. Solutions with pH below 6.5 or above 8.0 cause stinging on injection and accelerate semaglutide degradation.

What is disodium phosphate dihydrate? A pH buffer that maintains Wegovy's solution at pH 7.4. It prevents semaglutide degradation, which accelerates at pH below 7.0 or above 8.0. The phosphate buffer system resists pH changes when small amounts of acid or base are introduced during manufacturing or storage.

Does Wegovy contain latex? No. All rubber seals and components are made from synthetic rubber (bromobutyl or chlorobutyl) to prevent allergic reactions in latex-sensitive patients.

Why does Wegovy expire 56 days after first use? The 5.5 mg/mL phenol concentration prevents microbial growth during normal use but does not provide indefinite sterility. After 56 days, phenol may degrade or microbial bioburden may exceed what the phenol can suppress. The expiration is about microbial safety, not semaglutide potency.

Can I use Wegovy if I have a phenol allergy? Phenol sensitivity (not a true IgE-mediated allergy) causes injection site reactions in about 2% of patients. If you have documented phenol sensitivity, consider a compounded semaglutide formulation with benzyl alcohol preservative instead, or discuss alternatives with your provider.

What is the difference between Wegovy and Ozempic ingredients? The inactive ingredients are identical. The difference is semaglutide concentration (Wegovy 3.2 mg/mL vs Ozempic 1.34 or 2.68 mg/mL) and pen design (Wegovy single-dose vs Ozempic multi-dose). The maximum approved dose also differs (Wegovy 2.4 mg vs Ozempic 2 mg).

Does Wegovy contain any sugars or carbohydrates? No. Wegovy contains no sugars, sugar alcohols, or carbohydrates. It contributes zero grams of carbohydrate per injection.

Why do some compounded semaglutide formulations cause more injection site pain than Wegovy? Most compounded formulations use benzyl alcohol as the preservative instead of phenol. Benzyl alcohol causes more injection site stinging than phenol in head-to-head studies. Some compounded formulations also have lower pH (6.0 to 6.5 vs Wegovy's 7.4), which increases pain.

Can I mix Wegovy with other medications in the same syringe? No. Wegovy is formulated as a single-agent injection. Mixing it with other medications can alter pH, cause precipitation, or introduce contamination. Each medication should be injected separately.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Mathaes R et al. Subcutaneous Injection Volume-Dependent Pain Perception. Pharmaceutical Research. 2019.
5. Jorgensen L et al. Formulation stability and bioavailability of semaglutide in different excipient systems. Journal of Pharmaceutical Sciences. 2021.
6. Lee SH et al. Pain perception with benzyl alcohol versus phenol preserved injectable formulations. Pain Medicine. 2018.
7. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
8. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
9. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
10. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2019.
11. Novo Nordisk. Wegovy (semaglutide) injection Prescribing Information. FDA Label. 2021.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. FDA. Inactive Ingredient Search for Approved Drug Products. Drugs@FDA Database. 2026.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Humalog and Novolog are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ {"@type": "Question", "name": "What is the active ingredient in Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "Semaglutide, a GLP-1 receptor agonist. It is a modified version of human GLP-1 with three structural changes that extend its half-life to 7 days, allowing once-weekly dosing."}}, {"@type": "Question", "name": "What are the inactive ingredients in Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "Disodium phosphate dihydrate, propylene glycol, phenol, water for injection, sodium hydroxide, and hydrochloric acid. These stabilize semaglutide, control pH, prevent bacterial growth, and maintain osmolality for subcutaneous injection."}}, {"@type": "Question", "name": "Does Wegovy contain any preservatives?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. Wegovy contains phenol at 5.5 mg/mL, which prevents bacterial growth after the pen is first used. However, the FDA classifies Wegovy as preservative-free because the phenol concentration is below the 0.9% threshold for preserved labeling."}}, {"@type": "Question", "name": "Is compounded semaglutide the same as Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "The active ingredient (semaglutide) is the same. The inactive ingredients differ. Compounded formulations typically use saline base and benzyl alcohol preservative instead of Wegovy's propylene glycol/phosphate buffer and phenol. These differences can affect injection site tolerability and potentially absorption kinetics."}}, {"@type": "Question", "name": "What is propylene glycol and why is it in Wegovy?", "acceptedAnswer": {"@type": "Answer", "text": "Propylene glycol is a co-solvent that increases semaglutide solubility